Surgical Menopause: What Changes After the Ovaries Are Removed and How It Is Managed

The phrase showed up in a group chat before it showed up in a clinic: “They took out the black box.” In November 2025 the US Food and Drug Administration announced it would remove the boxed warning, its most prominent safety label, from most systemic menopausal hormone therapy products, citing a reanalysis of trial data in younger women. As of February 2026, searches for surgical menopause have climbed alongside, because this is the group that guidelines have long treated differently: people whose ovaries were removed before their bodies would have stopped making hormones on their own.

A 38-year-old recovering from endometriosis surgery, a 44-year-old with a BRCA1 variant who chose risk-reducing surgery, a 56-year-old wondering whether her ovaries should have come out with her uterus. Their questions overlap but their answers do not.

What follows is the long version: what actually changes in the body, what the trials and cohort studies can and cannot tell us, and where the decisions genuinely belong to the clinician who knows your history.

What is surgical menopause, and how is it different from natural menopause?

Natural menopause is a slow dimming. Over four to eight years the ovaries release fewer eggs, estrogen wobbles and then settles low, and the body adjusts in stages. Surgical menopause skips the stages. When both ovaries are removed, an operation called bilateral oophorectomy, the main source of estrogen and roughly half of the body’s testosterone disappears in a single afternoon. Menopause is dated to the day of surgery, whatever the person’s age.

Two details matter. Removing one ovary (unilateral oophorectomy) does not cause surgical menopause; the remaining ovary usually keeps working, although some observational data suggest natural menopause may arrive a little earlier. The uterus is a separate question, too. A hysterectomy, removal of the uterus, ends periods but does not by itself end ovarian hormone production. Only ovary removal does that.

Feature	Natural menopause	Surgical menopause
Onset	Gradual, over years of perimenopause	Abrupt, from the day of surgery
Typical age	About 51 in the US	Any age; often before 50 when done for benign disease or cancer risk reduction
Hormone change	Estrogen declines unevenly, then settles	Estradiol falls within about 24–48 hours; ovarian testosterone is also lost
Symptom intensity	Variable, often milder	Frequently sudden and severe (observational data)
Long-term risk	Age-expected baseline	Faster bone loss; higher cardiovascular and cognitive risk in cohort studies when done before about age 46 without estrogen
Usual approach	Symptom-based, individualized	Hormone therapy to about age 51 is generally advised unless contraindicated

Ovaries are removed to treat ovarian cysts or cancer, severe endometriosis, or as risk-reducing surgery for people carrying BRCA1 or BRCA2 gene variants, and sometimes alongside a hysterectomy for other benign conditions. The reason for surgery shapes everything that follows, which is why this article keeps handing the final call back to the surgical team and the follow-up clinician.

Why does the body react so strongly when both ovaries are removed?

Think of estrogen less as a reproductive hormone and more as a maintenance crew that visits almost every tissue. It steadies the temperature-control center in the hypothalamus, the part of the brain that decides when you are too hot. It restrains osteoclasts, the cells that dissolve bone. It helps the lining of blood vessels relax, keeps vaginal and urinary tissue thick and elastic, and influences sleep architecture, mood circuits and skin collagen.

In natural menopause that crew leaves gradually, and the body recruits backup: fat tissue converts adrenal and ovarian androgens into a weaker estrogen called estrone. After bilateral oophorectomy, blood estradiol drops to postmenopausal levels within about one to two days, and the ovarian share of androgens goes with it. The adrenal glands still produce some testosterone precursors, but the backup system is smaller and slower to compensate.

Hot flashes illustrate the mechanism well. A cluster of neurons in the hypothalamus, often called KNDy neurons, becomes overactive when estrogen falls away, narrowing the body’s comfortable temperature range. A tiny rise in core temperature then triggers a full heat-dumping response: flushing, sweating, a racing heart. This is the pathway that the newer non-hormonal drugs target, which is why they work in both natural and surgical menopause.

There is also a timing problem that natural menopause never has. Surgical menopause lands on top of anesthesia, wound healing, pain medication and disrupted sleep. For the first few weeks it can be hard to tell which symptom belongs to recovery and which to hormones, and clinicians usually ask people to keep a simple diary of hot flashes, sleep and mood so the picture becomes clearer by the six-week review.

What changed recently: the news behind the search spike

Several dated developments explain why surgical menopause is being searched so heavily right now.

On 10 November 2025 the FDA announced plans to remove the boxed warning covering cardiovascular disease, breast cancer and probable dementia from systemic menopausal hormone therapy labels, while keeping a warning about endometrial cancer for estrogen used alone by people who still have a uterus. The agency framed the move as a correction of how 2002 Women’s Health Initiative findings in women averaging 63 years old had been generalized to much younger women. The underlying evidence did not change in November; the label did.

In October 2025 the FDA approved elinzanetant, a non-hormonal drug that blocks neurokinin 1 and 3 receptors in the hypothalamus, for moderate to severe hot flashes. It followed fezolinetant, approved in May 2023, whose label gained a liver-monitoring warning in 2024. Both were studied in women with natural and surgical menopause, giving this group its first dedicated non-hormonal options since a paroxetine product was approved in 2013.

Guidance has been converging as well. The Menopause Society’s 2022 hormone therapy position statement, the UK’s updated NICE menopause guideline in November 2024, and patient pages from Mayo Clinic and Cleveland Clinic all state the same core principle: people who enter menopause before about age 45 to 50 because of surgery should generally be offered hormone therapy until around 51 unless there is a specific reason not to, because the aim is replacement, not addition.

Finally, surgical practice itself has shifted. Since evidence emerged that many aggressive ovarian cancers begin in the fallopian tubes, surgeons increasingly offer removal of the tubes alone (opportunistic salpingectomy) at the time of hysterectomy for average-risk patients, keeping the ovaries and avoiding surgical menopause altogether.

Surgical menopause symptoms: what the first weeks and months can feel like

Ask people what surprised them and the answer is rarely the hot flashes themselves. It is the speed. Many describe night sweats within the first week after surgery, often before the incisions have healed. Roughly three in four women experience hot flashes in natural menopause; in observational studies, those after oophorectomy tend to report them as more frequent and more severe, which fits the steeper hormonal drop.

Sleep usually goes next. Night sweats fragment it, but estrogen loss also affects sleep directly, and the result is a tiredness that rest does not fix. Mood changes follow for some: irritability, a flat low feeling, anxiety that arrives without an obvious trigger. People with a history of depression or premenstrual mood symptoms appear to be more vulnerable in cohort data.

Then come the quieter changes over the first several months. Vaginal dryness and discomfort with sex, a new urgency to urinate or recurrent urinary tract infections, joint aches that move around, dry skin and eyes, thinning hair, and a sense of mental fog that makes names and words slippery. Sex drive may fall, partly from estrogen loss and partly from the missing ovarian testosterone.

Not everyone has every symptom, and intensity varies widely. Age at surgery matters: a 30-year-old generally feels the loss more sharply than a 49-year-old who was already in perimenopause. Whether hormone therapy is started promptly, and whether the operation was for cancer or for benign disease, shape the experience too.

The practical point is that these symptoms are expected consequences of a sudden hormone change, not a sign that something went wrong in the operating room. They are also, for most people, treatable, which is where the rest of this piece heads.

Menopause after hysterectomy: does removing the uterus alone cause it, and what is an elective hysterectomy?

An elective hysterectomy is a planned, non-emergency removal of the uterus for a condition that is not cancer, such as heavy menstrual bleeding, fibroids (benign muscular growths of the uterine wall), endometriosis, adenomyosis or pelvic organ prolapse. “Elective” describes the scheduling, not the seriousness; the symptoms that lead to it can be life-limiting.

Removing the uterus alone does not cause menopause, because the uterus makes no sex hormones. Periods stop, but the ovaries keep producing estrogen, progesterone and androgens until they wind down naturally. That said, several observational studies suggest hysterectomy with ovarian conservation may bring natural menopause forward by roughly one to four years, perhaps because the operation disturbs blood flow to the ovaries. This is association, not proof, and the effect size varies between studies.

The tricky part is recognition. Without periods, the usual signpost of menopause is gone. Someone who had a hysterectomy at 42 and starts waking drenched at 47 may not connect the two. Blood tests for follicle-stimulating hormone can help but fluctuate, so clinicians generally rely on symptoms and age together.

The decision to remove ovaries during a hysterectomy has changed markedly. For premenopausal patients at average risk of ovarian cancer, professional guidance now leans toward keeping the ovaries and offering removal of the fallopian tubes instead, given cohort evidence of long-term harm from early estrogen loss. For people at high genetic risk, or with ovarian disease, removal remains the standard recommendation.

If both ovaries are removed but the uterus stays, as happens in some endometriosis or cancer-risk surgeries, hormone therapy later must include a progestogen to protect the uterine lining. If the uterus is also removed, estrogen alone is usually used. That distinction drives much of the prescribing discussion in the sections ahead.

Long-term oophorectomy side effects: bones, heart and brain

The short-term symptoms are loud. The long-term oophorectomy side effects are quiet, which is exactly why guidelines pay so much attention to them.

Bone comes first. Estrogen keeps bone breakdown in check, and when it vanishes overnight the balance tips toward loss. Bone density falls fastest in the first few years after surgery, and the earlier the surgery, the more decades of lower density lie ahead. Osteoporosis, a condition in which bones become porous enough to fracture from a minor fall, becomes more likely without estrogen replacement or other protection.

Cardiovascular disease is the second concern. In the Nurses’ Health Study, a cohort following more than 29,000 women after hysterectomy, those who also had both ovaries removed before 50 and never used estrogen had higher rates of coronary heart disease and death from any cause than women who kept their ovaries. The Mayo Clinic Cohort Study of Oophorectomy and Aging found similar patterns, including higher rates of multiple chronic conditions when surgery happened before about 46.

Brain health is the third. The Mayo cohort also reported higher long-term risks of cognitive impairment and parkinsonism after early oophorectomy, with the excess risk concentrated in women who did not take estrogen until around 50. Mood disorders, including anxiety and depression, were more common as well.

Every one of these findings is observational. Women who have their ovaries removed early may differ in ways that influence outcomes, and no trial has randomized young women to surgery with or without estrogen. Still, the consistency across cohorts, the plausible mechanisms, and the apparent protective effect of estrogen replacement in those same datasets are why professional bodies treat surgical menopause before 45 to 50 as a condition to be actively managed rather than simply weathered.

What the evidence actually says, and how strong it is

Honest readers deserve an honest grading, because the evidence here is a patchwork of strong and weak threads.

Randomized trial evidence exists mainly for hormone therapy in women near the usual age of menopause. The Women’s Health Initiative estrogen-alone arm enrolled about 10,700 women who had already had a hysterectomy, average age 63. It found increased stroke and blood clot risk, no increase in breast cancer, and, in the subgroup aged 50 to 59, a pattern of fewer heart events and lower mortality that did not reach the older groups. Smaller trials such as KEEPS and ELITE in recently menopausal women found neutral to favorable effects on vascular markers. None of these trials enrolled many women in their 30s or early 40s after oophorectomy.

For that younger group the evidence is observational: the Nurses’ Health Study, the Mayo Clinic cohort, Danish and Swedish registry analyses. They point the same way, toward harm from early estrogen loss and attenuation of that harm with estrogen use to around 50, but they cannot prove cause. A randomized trial withholding estrogen from 35-year-olds after surgery would be considered unacceptable, so the observational data are likely as good as this question will get.

Non-hormonal hot flash treatments stand on firmer trial ground. Fezolinetant and elinzanetant each have phase 3 randomized trials showing meaningful reductions in hot flash frequency and severity versus placebo, with surgical menopause participants included. Cognitive behavioral therapy and clinical hypnosis have randomized trials showing reduced hot flash distress.

The recommendation to continue hormone therapy until around age 51 is, strictly speaking, expert consensus informed by the cohort data, not a trial result. Testosterone for low desire after surgical menopause rests on randomized trials that mostly enrolled women in natural menopause. Knowing which claims rest on which foundations is the fastest way to spot a viral oversimplification.

HRT after oophorectomy: who guidelines say should consider it

The logic of HRT after oophorectomy is replacement. A 40-year-old whose ovaries have been removed is not adding hormones her body would have stopped making; she is restoring roughly what it would have produced for another decade. That framing is why the Menopause Society, NICE, Mayo Clinic and Cleveland Clinic all describe hormone therapy as the usual approach for surgical menopause before the typical age of natural menopause, continued to about 51, unless there is a specific contraindication.

Which hormones depends on anatomy. If the uterus has been removed, estrogen alone is generally used. If the uterus remains, a progestogen is added to protect the uterine lining from estrogen-driven overgrowth. Estrogen comes as tablets, skin patches, gels and sprays; observational data suggest skin-applied estrogen carries a lower risk of blood clots than tablets, and clinicians often favor it when clot risk is a concern. Formulation, route and duration are prescribing decisions for the clinician, and this article deliberately gives no doses.

Contraindications include a history of estrogen-sensitive breast cancer, an active or recent blood clot, unexplained vaginal bleeding, and certain liver conditions. For people with a BRCA1 or BRCA2 variant who have had risk-reducing surgery but have never had breast cancer, observational studies have not shown a rise in breast cancer with hormone therapy used up to the usual menopausal age, and specialist bodies generally support offering it. Severe endometriosis calls for a tailored discussion, since estrogen can occasionally reactivate residual tissue.

What about continuing past 51? At that point the person is in the same position as anyone else in menopause, and the decision rests on symptoms, personal risk and preference. Nobody should stop or alter prescribed hormone therapy on the strength of a headline; the right venue for that conversation is the clinician who prescribed it.

How are hot flashes treated without hormones, including in older adults?

Some people cannot take estrogen, some prefer not to, and some are well past the age at which guidelines support starting it. Systemic hormone therapy is generally not initiated for hot flashes alone after age 60 or more than ten years from menopause, because trial data show the balance of cardiovascular and stroke risk shifts in that window. That leaves a growing menu of other options.

Two prescription drugs act directly on the brain’s overactive temperature neurons: fezolinetant, approved in 2023, and elinzanetant, approved in 2025. Both reduced hot flash frequency and severity in randomized trials. Fezolinetant requires blood tests for liver function according to its label, and elinzanetant commonly causes drowsiness, which deserves attention in older adults at risk of falls.

Several antidepressants reduce hot flashes at a different point in the pathway. A paroxetine product is FDA-approved specifically for this purpose; other SSRIs and SNRIs such as venlafaxine are used by clinicians based on trial evidence, which is off-label in the US, a decision that belongs to the prescriber. Gabapentin, oxybutynin and clonidine have smaller supporting trials; the NHS lists clonidine and gabapentin among its non-hormonal options.

Non-drug approaches hold up better than many expect. Cognitive behavioral therapy designed for menopause reduces how much hot flashes disrupt life and improves sleep, and clinical hypnosis cut hot flash frequency in randomized trials. Keeping the bedroom cool, dressing in layers and limiting alcohol and spicy food help some people, though the trial evidence is thin. Supplements such as black cohosh and soy isoflavones have mixed and mostly weak evidence.

For older adults specifically, kidney function, other medicines and fall risk guide which option fits. Vaginal estrogen for dryness and urinary symptoms is considered appropriate at any age by major guidelines because very little is absorbed into the bloodstream.

Should the ovaries be removed after menopause? Weighing the trade-offs

Here is a detail many people learn only in a surgeon’s office: the ovaries do not retire at menopause. They stop releasing eggs and making estradiol, but they continue producing testosterone and androstenedione for years, and fat tissue converts some of that into estrone. So removing the ovaries at 58 is not hormonally neutral, even though it does not trigger surgical menopause in the classic sense.

The potential downsides of removing healthy ovaries after menopause fall into two groups. The first is surgical: bleeding, infection, injury to nearby organs, anesthesia risk and a slightly longer operation if done alongside hysterectomy. The second is hormonal and less certain. Some women report a drop in sexual desire or energy afterward, consistent with the lost androgens. Large cohort analyses of mortality give a mixed picture: the Nurses’ Health Study found no survival advantage from removing ovaries at any age, with the clearest harm before 50, while other analyses found little difference after 55. Expert bodies describe the postmenopausal decision as individualized rather than settled.

The upside is real too. Removal eliminates ovarian cancer, a disease with a lifetime risk of roughly one to two percent in the general population and far higher in people with BRCA variants or Lynch syndrome, for whom removal is clearly recommended. It also removes the possibility of future ovarian cysts or a second operation.

Because many aggressive ovarian cancers start in the fallopian tubes, removing the tubes while keeping the ovaries is now a common middle path for average-risk patients having a hysterectomy. Whether that or full removal is right depends on age, genetic risk, personal history and how much weight a person places on each kind of risk. It is a conversation for the gynecologic surgeon, ideally before the operation is scheduled.

Sexual health, vaginal changes and the testosterone question

Few symptoms are discussed less and treated more easily than this group. Genitourinary syndrome of menopause, usually shortened to GSM, is the medical name for the thinning, dryness and loss of elasticity in vaginal and urinary tissue that follows estrogen loss. Unlike hot flashes, it does not fade with time; left alone it tends to progress.

Vaginal estrogen, applied locally as a cream, tablet or ring, restores tissue thickness and reduces painful sex and recurrent urinary infections, with minimal absorption into the bloodstream. Major guidelines consider it appropriate even for people who cannot use systemic hormones, with specific caveats for those with breast cancer that belong to the oncology team. Non-hormonal vaginal moisturizers used regularly and lubricants during sex help as well, and pelvic floor physical therapy addresses muscle tension that often develops around pain.

Desire is more complex. Surgical menopause removes ovarian testosterone, and some people notice a distinct loss of libido that persists even when estrogen is replaced. Randomized trials, summarized in a 2019 global consensus statement, show that testosterone therapy modestly improves sexual desire in postmenopausal women with distressing low desire. Two cautions apply. Most trial participants were in natural menopause, so the evidence in surgical menopause specifically is thinner. And in the US there is no FDA-approved testosterone product for women, meaning any prescription is off-label and any decision rests with the treating clinician after estrogen has been addressed. Compounded testosterone products are not standardized and are not a self-treatment route.

Relationship and mood factors deserve equal billing. Pain, fatigue, grief about fertility and body changes after surgery all shape desire, and sex therapy or couples counseling has evidence for improving sexual satisfaction regardless of hormone status.

Everyday care after surgical menopause: bone, heart, sleep and mood

Hormone decisions grab the attention, but the daily scaffolding matters as much over the decades that follow surgical menopause.

Bone protection starts with knowing where you stand. Many clinicians arrange a bone density scan, called a DEXA scan, within a year or two of early oophorectomy and repeat it based on results. Weight-bearing exercise such as brisk walking and resistance training two or more days a week stimulate bone to rebuild. Calcium and vitamin D intake should meet the daily amounts recommended for your age, which the NIH Office of Dietary Supplements lists by life stage; food sources come first, with supplements only to fill a gap identified with a clinician.

Heart care follows familiar lines with extra urgency. The American Heart Association’s general targets, including at least 150 minutes of moderate activity each week, a Mediterranean-style eating pattern, not smoking and regular checks of blood pressure, cholesterol and blood sugar, apply to everyone, but early estrogen loss moves the timeline forward. A clinician may suggest cardiovascular risk assessment earlier than the usual age.

Sleep deserves its own plan rather than being left to improve on its own. Cognitive behavioral therapy for insomnia has stronger trial evidence than sleeping tablets and no dependence risk, and it works alongside treatment of night sweats. A cooler bedroom, consistent wake times and limiting alcohol in the evening are modest but real helps.

Mood should be asked about at every follow-up, not only when it becomes a crisis. Depression and anxiety are more common after early oophorectomy in cohort studies, and both respond to psychological therapy and medication. Grief is also legitimate, particularly when surgery ended fertility sooner than planned, and support groups or counseling can carry that part of recovery that no prescription addresses.

Common myths about surgical menopause

Viral posts about surgical menopause tend to be half right, which makes them harder to correct than outright nonsense.

Myth one: a hysterectomy means instant menopause. Only ovary removal does. Removing the uterus ends periods and may nudge natural menopause a few years earlier in observational data, but hormone production continues.

Myth two: hormone therapy after surgical menopause carries the same breast cancer risk reported in 2002. The Women’s Health Initiative studied women averaging 63; its estrogen-alone arm, the closest match to people without a uterus, did not show an increase in breast cancer. For someone in her 30s or 40s after oophorectomy, hormone therapy to around 51 replaces what the body would otherwise have made. The risk picture is different, which is part of why the FDA revisited its labeling in 2025.

Myth three: you will be on hormones forever. Guidelines frame replacement to the usual menopausal age as the baseline; continuing beyond that is a separate, individual decision.

Myth four: symptoms always settle within a year. Hot flashes often ease over time, though for some they persist for many years, and genitourinary symptoms tend to worsen without treatment.

Myth five: compounded “bioidentical” hormones are safer because they are natural. Compounded products are not FDA-approved, are not tested for consistent dosing or purity, and are not a self-treatment option. FDA-approved estradiol and micronized progesterone are themselves molecularly identical to the body’s hormones.

Myth six: people with BRCA variants can never use hormone therapy. Observational studies in BRCA carriers without breast cancer have not shown increased breast cancer with hormone therapy used until the usual age of menopause after risk-reducing surgery, and specialist guidance generally supports offering it.

Myth seven: ovaries are useless after menopause. They keep making androgens for years, which is why their removal later in life remains a weighed decision rather than an automatic add-on.

When to see a doctor

Some symptoms after oophorectomy are expected. Others need the same day, and knowing the difference is part of safe recovery.

In the weeks after surgery, seek urgent care for fever, worsening abdominal pain, heavy vaginal bleeding, redness or discharge from an incision, pain or swelling in one calf, chest pain, or sudden breathlessness. The last three can signal a blood clot, a recognized risk after pelvic surgery.

For anyone taking hormone therapy, red flags include a swollen or painful leg, sudden chest pain or shortness of breath, a severe or unusual headache, sudden vision or speech changes, weakness on one side, a new breast lump, or any vaginal bleeding if the uterus was retained. These warrant prompt assessment; do not simply stop the medicine on your own, because the clinician needs to evaluate the symptom and decide the next step.

Mood changes deserve a low threshold too. Persistent low mood, loss of interest, panic, or thoughts of self-harm are reasons to contact a clinician promptly. In the US, the 988 Suicide and Crisis Lifeline is available by call or text at any hour.

Schedule a routine visit, rather than waiting, if hot flashes or night sweats are wrecking sleep, if sex has become painful, if urinary infections keep recurring, if you are falling or have broken a bone from a minor stumble, or if you had a hysterectomy years ago and new symptoms make you wonder whether menopause has arrived.

Finally, before any planned oophorectomy, ask what the plan for afterward will be: whether hormone therapy is appropriate for you, who will prescribe and follow it, and when bone and heart checks will happen. Surgical menopause is far more manageable when that conversation occurs before the operation than when it is improvised afterward.

Frequently asked questions

What are the common symptoms of postmenopause?

Hot flashes, night sweats, disturbed sleep, vaginal dryness, discomfort during sex, urinary urgency or infections, joint aches, mood changes and difficulty concentrating are the most common. Hot flashes tend to ease over the years for many people, while vaginal and urinary symptoms usually persist or worsen without treatment. Bone loss and rising cardiovascular risk are silent changes that a clinician monitors rather than symptoms you would feel.

How can hot flashes be treated in older adults (the elderly)?

Guidelines generally advise against starting systemic hormone therapy for hot flashes alone after age 60 or more than ten years past menopause, so non-hormonal options come first. These include fezolinetant and elinzanetant, a paroxetine product approved for hot flashes, other antidepressants, gabapentin, cognitive behavioral therapy and clinical hypnosis. Kidney function, other medicines and fall risk guide the choice, which belongs to the treating clinician.

What is an elective hysterectomy?

An elective hysterectomy is a planned, non-emergency removal of the uterus for a benign condition such as fibroids, heavy bleeding, endometriosis, adenomyosis or prolapse. The word refers to scheduling, not to the seriousness of the symptoms. Removing the uterus alone does not cause menopause; whether the ovaries are also removed is a separate decision based on age, cancer risk and ovarian health.

What are the potential side effects of having an ovary removed after menopause?

Postmenopausal ovaries still make androgens, so removal can lower sexual desire and energy in some people, alongside the usual surgical risks of bleeding, infection and injury to nearby organs. Large cohort studies show no clear survival benefit from removing healthy ovaries after menopause and mixed results on long-term outcomes. Removal does eliminate ovarian cancer risk, which is why it is recommended for people at high genetic risk.

How soon do surgical menopause symptoms start after the operation?

Often within days. Estradiol drops to postmenopausal levels within about one to two days of bilateral oophorectomy, and many people notice night sweats or hot flashes in the first week, before incisions have healed. Sleep and mood changes typically follow within weeks, while vaginal dryness and urinary symptoms develop over months. Starting hormone therapy promptly, when appropriate, can blunt the early intensity.

Does surgical menopause cause weight gain?

Menopause itself shifts where fat is stored, toward the abdomen, and lowers resting energy use modestly, but trial data do not show that hormone changes alone cause large weight gain. Reduced activity during recovery, poor sleep and age all contribute. Hormone therapy does not cause weight gain in randomized trials. Regular resistance and aerobic exercise and a Mediterranean-style eating pattern are the evidence-based countermeasures.

Is HRT after oophorectomy safe for someone with a BRCA mutation?

For BRCA1 or BRCA2 carriers who have had risk-reducing removal of the ovaries and tubes and have never had breast cancer, observational studies have not shown an increase in breast cancer with hormone therapy used until the usual age of menopause, and specialist guidance generally supports offering it. The picture differs for anyone with a personal breast cancer history. The decision rests with the treating team.

How long does surgical menopause last?

Menopause is permanent once both ovaries are removed, but the symptoms are not fixed. Hot flashes and night sweats often ease over several years, with wide individual variation, and some people have them for a decade or more. Vaginal and urinary symptoms tend to persist or worsen without treatment. Bone and heart effects continue over a lifetime, which is why follow-up extends well beyond the symptomatic phase.

Can I keep one ovary and avoid surgical menopause?

Usually yes, if the remaining ovary is healthy. One ovary generally produces enough hormones to prevent surgical menopause, although some observational studies suggest natural menopause may arrive slightly earlier. Whether keeping an ovary is advisable depends on why surgery is needed; for ovarian cancer or a high genetic risk, surgeons recommend removing both. For benign conditions, ovarian conservation is often preferred before natural menopause.

Does surgical menopause raise the risk of dementia?

Cohort studies, notably the Mayo Clinic Cohort Study of Oophorectomy and Aging, found higher long-term rates of cognitive impairment in women who had both ovaries removed before about age 45 to 50, with the excess concentrated in those who did not take estrogen until around 50. This is observational evidence, not proof of cause, but it is one reason guidelines favor hormone therapy to the usual menopausal age when there is no contraindication.

References

• NHS: Menopause, treatment
• MedlinePlus: Menopause

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.